|
Jun 3
|
Novartis reports topline outcomes from trial of Pluvicto for prostate cancer
|
|
Jun 2
|
ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP
|
|
Jun 2
|
Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure
|
|
Jun 2
|
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
|
|
Jun 2
|
Novartis’s Cancer Treatment Pluvicto Shows Positive Results in Trial
|
|
Jun 2
|
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
|
|
Jun 1
|
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
|
|
May 30
|
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
|
|
May 27
|
What Makes Novartis AG (NVS) a Differentiated Business?
|
|
May 27
|
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
|
|
May 21
|
Market Chatter: Court Denies Novartis' Motion to Dismiss Lawsuit Alleging Asthma Drug Caused Autism
|
|
May 21
|
Are You Looking for a High-Growth Dividend Stock?
|
|
May 19
|
Judge shuts down drugmakers’ 340B rebate plans, for now
|
|
May 15
|
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
|
|
May 15
|
Should Value Investors Buy Novartis (NVS) Stock?
|
|
May 15
|
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
|
|
May 15
|
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
|
|
Apr 25
|
Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca
|
|
Apr 23
|
Update: Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|